Position in CDXS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$460,279
-$238,862 QoQ
Shares Held
282,380
-34.2% QoQ
Ownership
0.311%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CDXS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026LAZARD ASSET MANAGEMENT LLC holds $357,993,489 across 55 Biotechnology names. CDXS ranks #36 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARGX |
Argenx SE
|
133,347 | $97,376,646 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
213,131 | $95,171,516 | |
| 3 | INCY |
Incyte Corp
|
219,881 | $20,695,199 | |
| 4 | ONC |
BeOne Medicines Ltd.
|
62,917 | $18,684,461 | |
| 5 | BMRN |
Biomarin Pharmaceutical Inc
|
325,851 | $18,407,322 | |
| 6 | EXEL |
Exelixis, Inc.
|
372,600 | $15,980,814 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
17,004 | $13,137,970 | |
| 8 | JAZZ |
Jazz Pharmaceuticals plc
|
42,723 | $8,076,783 |
All Filings in CDXS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $460,279 | 282,380 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $699,141 | 428,921 | Shares | Sole | 2026-02-17 | |
| 2022-09-30 | $38,014 | 6,273 | Shares | Sole | 2022-11-14 | |
| 2022-06-30 | $66,494 | 6,357 | Shares | Sole | 2022-08-09 | |
| 2020-09-30 | $50,939 | 4,339 | Shares | Sole | 2020-11-13 | |
| 2020-06-30 | $57,969 | 5,085 | Shares | Sole | 2020-08-13 | |
| 2020-03-31 | $42,441 | 3,803 | Shares | Sole | 2020-05-14 | |
| No filing history on record for this holder in this stock. | ||||||